stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Shares outstanding
Kymera Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $84.5M, up 12.6% from $75.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $100.1M. Over the past ten years it has ranged from $1.7M (fiscal 2019) to $84.5M (fiscal 2025) — the current reading is the highest in ten years. Kymera Therapeutics, Inc. ranks 151st of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $84.5M | 12.59% |
| FY2024 | $75.0M | 28.58% |
| FY2023 | $58.4M | 8.22% |
| FY2022 | $53.9M | 12.39% |
| FY2021 | $48.0M | 176.59% |
| FY2020 | $17.4M | 921.19% |
| FY2019 | $1.7M | (96.18%) |
| FY2018 | $44.5M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $100.1M | 1.96% |
| Jun 2026 | $98.2M | 0.66% |
| Mar 2026 | $97.5M | 15.44% |
| Dec 2025 | $84.5M | (3.22%) |
| 24 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| IBRX ImmunityBio, Inc. compare | $1.1B |
| SMMT Summit Therapeutics PLC compare | $778.2M |
| CAI Caris Life Sciences,�Inc. compare | $295.1M |
| BMRN BioMarin Pharmaceutical Inc. compare | $193.6M |
| TGTX TG Therapeutics, Inc. compare | $157.3M |
| TECH Bio-Techne Corp compare | $157.0M |
| PCVX Vaxcyte, Inc. compare | $144.5M |
| KYMR Kymera Therapeutics, Inc. | $100.1M |
| TWST Twist Bioscience Corporation compare | $62.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement